Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Shore ND, et al. Among authors: sarapohja t. Oncologist. 2024 Jul 5;29(7):581-588. doi: 10.1093/oncolo/oyae019. Oncologist. 2024. PMID: 38394384 Free PMC article. Clinical Trial.
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verholen F. Fizazi K, et al. Among authors: sarapohja t. Eur J Cancer. 2023 Oct;192:113258. doi: 10.1016/j.ejca.2023.113258. Epub 2023 Jul 27. Eur J Cancer. 2023. PMID: 37660438 Free article. Clinical Trial.
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study.
Shore ND, Fizazi K, Tammela TLJ, Luz M, Salas MP, Ouellette P Jr, Lago S, Bastos DA, Jansz GK, Cárcano FM, Andrade L, Pliskin M, Lazaretti N, Arruda L, Correa Ochoa JJ, Kuss I, Kappeler C, Sarapohja T, Smith M. Shore ND, et al. Among authors: sarapohja t. Eur J Cancer. 2023 Sep 17;195:113342. doi: 10.1016/j.ejca.2023.113342. Online ahead of print. Eur J Cancer. 2023. PMID: 39491396 Free article.
Feasibility and patient acceptability of a commercially available wearable and a smart phone application in identification of motor states in parkinson's disease.
Liikkanen S, Sinkkonen J, Suorsa J, Kaasinen V, Pekkonen E, Kärppä M, Scheperjans F, Huttunen T, Sarapohja T, Pesonen U, Kuoppamäki M, Keränen T. Liikkanen S, et al. Among authors: sarapohja t. PLOS Digit Health. 2023 Apr 7;2(4):e0000225. doi: 10.1371/journal.pdig.0000225. eCollection 2023 Apr. PLOS Digit Health. 2023. PMID: 37027348 Free PMC article.
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022].
Bögemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Lebret T, Schostak M, Verholen F, Le Berre MA, Srinivasan S, Ortiz J, Mohamed AF, Sarapohja T, Fizazi K. Bögemann M, et al. Among authors: sarapohja t. Eur Urol. 2023 Feb;83(2):e60. doi: 10.1016/j.eururo.2022.11.018. Epub 2022 Dec 14. Eur Urol. 2023. PMID: 36526492 Free article. No abstract available.
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Lebret T, Schostak M, Verholen F, Le Berre MA, Srinivasan S, Ortiz J, Mohamed AF, Sarapohja T, Fizazi K. Bögemann M, et al. Among authors: sarapohja t. Eur Urol. 2023 Mar;83(3):212-221. doi: 10.1016/j.eururo.2022.07.018. Epub 2022 Sep 9. Eur Urol. 2023. PMID: 36089529 Free article. Clinical Trial.
A prospective, double-blind, pilot, randomized, controlled trial of an "embodied" virtual reality intervention for adults with low back pain.
Eccleston C, Fisher E, Liikkanen S, Sarapohja T, Stenfors C, Jääskeläinen SK, Rice ASC, Mattila L, Blom T, Bratty JR. Eccleston C, et al. Among authors: sarapohja t. Pain. 2022 Sep 1;163(9):1700-1715. doi: 10.1097/j.pain.0000000000002617. Epub 2022 Mar 25. Pain. 2022. PMID: 35324507 Free PMC article. Clinical Trial.
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamäki M, Garratt C, Al-Chalabi A; REFALS investigators. Cudkowicz M, et al. Among authors: sarapohja t. Lancet Neurol. 2021 Oct;20(10):821-831. doi: 10.1016/S1474-4422(21)00242-8. Lancet Neurol. 2021. PMID: 34536404
29 results